Stem Cells Market Outlook:
Stem Cells Market size was over USD 15.86 billion in 2024 and is poised to exceed USD 45.85 billion by 2034, witnessing over 11.2% CAGR during the forecast period i.e., between 2025-2034. In the year 2025, the industry size of stem cell treatment is evaluated at USD 17.37 billion.
Key Stem Cell Market Insights Summary:
North America’s stem cell market share is anticipated to reach 39% by the close of 2034.
The Asia Pacific stem cell market is forecasted to account for roughly 24% of the market by 2034.
The allogeneic segment is projected to hold approximately 43% of the stem cell market share by 2034.
The regenerative medicine segment is expected to capture a substantial stem cell market share of around 57% by 2034.
Key Growth Trends:
- Rising Prevalence of Musculoskeletal Disorders Such as Osteoarthritis
- Establishment of New Research and Therapy Center for Stem Cells and Cancer
Key Players:
- Stemedica Cell Technologies, Inc., Pluristem Therapeutics Inc., Thermo Fisher Scientific, Becton, Dickinson and Company, Advanced Cell Technology Inc., Cellular Engineering Technologies Inc., CellGenix GmbH, PromoCell GmbH, Kite Pharma, Genea Biocells.
Market Size and Growth Projections:
- 2024 Market Size: USD 15.86 billion
- 2025 Market Size: USD 17.37 billion
- Projected Market Size: USD 45.85 billion by 2034
- Growth Forecasts: 11.2% CAGR (2025-2034)
- Largest Region: North America (39% Share by 2034)
- Fastest Growing Region: North America
The market growth is driven by growing prevalence of chronic diseases such as, cancer, sickle cell disease, lymphoproliferative disorders, tumors, and others. According to WHO, cancer accounted for nearly ten million deaths worldwide in 2020. A study conducted by the International Agency for Research on Cancer 2020 found that approximately 1 in 5 people develops cancer during their lifetime, and about 1 in 8 men and 1 in 11 women die from it. Early diagnosis allows for a more targeted cancer treatment, such as stem cell therapy, which can be more effective than traditional chemotherapy and radiation treatments. Stem cell involve using stem cells to stimulate the body's own immune system to attack cancer cells. The stem cells can also be used to replace damaged cells and restore function to organs that have been damaged by cancer.
In addition, growing demand for regenerative and personalized medicines, and rise in government funding for stem cell research will impel the market revenue. Stem cells can be used to create personalized medicines tailored to the individual needs of a patient.
Stem Cells Market Growth Drivers and Challenges:
Growth Drivers
-
Rising Prevalence of Musculoskeletal Disorders Such as Osteoarthritis- According to the World Health Organization (WHO), nearly 1.71 billion people are affected by musculoskeletal conditions worldwide. According to the CDC, one in four US adults (or 54.4 million) suffer from some form of arthritis, with the number projected to rise to 78 million by 2040. The most common form of arthritis, osteoarthritis (OA), affects 32.5 million adults in the US. Stem cell can help to reduce pain, improve mobility and reduce inflammation associated with musculoskeletal disorders. This has led to an increased interest in stem cell as an alternative to traditional treatments such as surgery.
-
Establishment of New Research and Therapy Center for Stem Cells and Cancer - For instance, a new stem cell and cancer research and therapy center was inaugurated by the Global Institute of Stem Cell Therapy and Research (GIOSTAR) in Chandigarh, India, in February 2020. As part of GIOSTAR's global expansion efforts in India, Mexico, the United States, and other countries, this facility marks the latest milestone. Development of a new center can help drive innovation in the field of stem cell therapy, contributing to more effective treatments and better outcomes.
-
Increasing Number of Stem Cell-Based Clinical Trials - A preliminary review of 112 stem cell-based clinical trials has been conducted by May 2020. The best results were obtained using hematopoietic stem cells (37%), mesenchymal stem cells (35%), umbilical cord blood (UCB) (23%) and bone marrow (BM)-derived cells (21%).
-
Availability of Enormous Amounts of Funds for Stem Cell Research and Development- Research funding for stem cells has increased in recent years. Stem cell research is seen as a promising area of medicine, as it could lead to treatments for incurable diseases and injuries. For instance, a funding award of USD 31 million was granted to Stanford Research in September 2021 by the California Institute for Regenerative Medicine for launching first-in-human trials of stem cells for heart failure, strokes, and spinal cord tumours. Also, a Stem Cell SpaceShot Grant in the field of stem cell biology and regenerative medicine has been announced by TreeFrog Therapeutics in April 2022. The grant amounts to USD 100,000 in research funding.
-
Rise in Approval for Stem Cell for Type 1 Diabetes (T1D) - For instance, a clinical trial of VX-880 was initiated by Vertex Pharmaceuticals Incorporated in April 2021 after receiving FDA Fast Track Designation in April 2021. The company is testing it on patients with type 1 diabetes (T1D) who suffer from severe hypoglycemia and are unaware of their hypoglycemia. For the treatment of type 1 diabetes, VX-880 uses fully differentiated, insulin-producing pancreatic islet cells derived from stem cells.
Challenges
-
Ethical concerns related to the use of stem cells in treatments- The use of stem cells is highly regulated and can be a source of controversy due to potential ethical issues such as the potential for human embryos to be used in treatments. This has caused many countries to impose regulations on the use of stem cells and has limited the growth of the stem cell market.
-
High costs of treatment
-
Lack of availability of stem cell sources and the lack of standardization of stem cell
Stem Cells Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
11.2% |
|
Base Year Market Size (2024) |
USD 15.86 billion |
|
Forecast Year Market Size (2034) |
USD 45.85 billion |
|
Regional Scope |
|
Stem Cells Market Segmentation:
Treatment Type Segment Analysis
The allogeneic segment is estimated to account for 43% stem cell market share by 2034, owing to its ability to provide long-term benefits for patients, cost effectiveness, and the potential for personalized treatments. Additionally, advancements in stem cell technology and the increasing demand for stem cell therapies are further driving the growth of the allogeneic segment.
Moreover, increasing incidence of blood cancer and genetic disorders are also expected to fuel the segment growth. It is estimated that someone in the US die of a blood cancer every nine minutes. An estimated 57,750 people died from leukemia, lymphoma, and myeloma in the US in 2021. The number of Australians suffering from blood cancer or blood disorders today is around 135,000. Allogeneic stem cell transplant involves harvesting healthy stem cells from a donor and transplanting them into the patient. The healthy stem cells can then proliferate and replace the cancerous cells, allowing the patient to recover from the disease.
Application Segment Analysis
The regenerative medicine segment is set to gain significant stem cell market share of about 57% by 2034. The growth of the segment can be attributed to rising awareness and acceptance of regenerative medicine as regenerative medicine has the potential to revolutionize the healthcare industry by providing treatments for previously untreatable conditions with better outcomes.
According to current estimates, regenerative medicine is estimated to potentially have a significant impact on a staggering one out of three Americans. Additionally, advancements in technology have enabled the development of more advanced regenerative medicine treatments that are more effective, faster, and safer. Furthermore, the increasing government funding for regenerative medicine research is expected to lead to further advancements in the field.
Our in-depth analysis of the global market includes the following segments:
|
By Stem Cell Type |
|
|
By Treatment Type |
|
|
By Application |
|
|
By Stem Cell Technology |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Stem Cells Market Regional Analysis:
North American Market Insights
The market share of stem cell in North America is poised to reach 39% by the end of 2034. The market domination can be attributed to increasing awareness about the potential of stem cell , rising prevalence of chronic diseases such as diabetes, technological advancements in the field, and presence of favorable reimbursement policies in the region. According to the Centers for Disease Control and Prevention, a total of 37.3 million people have diabetes (about 11.3% of the US's population). 28.7 million people have been diagnosed, including 28.5 million adults.
Stem cell therapy is a promising new therapy for diabetes, as it has the potential to replace the damaged cells that are responsible for producing insulin. This could potentially restore the body's ability to regulate glucose levels and prevent serious complications of diabetes. Additionally, the increased investments by companies for research and development and rising number of clinical trials related to stem cell are also augmenting the market growth.
APAC Market Insights
Asia Pacific stem cell market is estimated to register a share of about 24% by the end of 2034, owing to rise of stem cell for a number of diseases, such as cancer, diabetes, and Parkinson's disease, has contributed to increased investment in research and development in the region, as well as increased access to stem cell . Furthermore, researchers in the region have achieved considerable success in the development and implementation of stem cell therapy techniques.
Stem cell therapy is observed to have a success rate of 65% to 85% in India, which is among the highest in the world. Also, 200 clinical trials for stem cell-based therapies have been enumerated in this study in order to determine the effectiveness of such therapies in China. As stem cell research continues to advance and more successful treatments become available, the potential applications of stem cell therapy continue to expand significantly, providing relief for patients suffering from chronic, degenerative and otherwise incurable diseases. Additionally, the cost of stem cell has decreased significantly in the region due to advancements in technology and the availability of more affordable treatments.
Europe Market Insights
Stem cell market in Europe is anticipated to hold a majority of the share by the end of 2034. The growth of the market is led by upsurge in number of cell therapy production owing to growing number of clinical trials and the increasing support from the government and private organizations to fund and promote this type of research. In addition, the increasing number of government initiatives to raise awareness about stem cell is contributing to market expansion. Moreover, technological advancements such as the development of induced pluripotent stem cells (iPSCs) will boost the regional market revenue.
Key Stem Cells Market Players:
- Stemedica Cell Technologies, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pluristem Therapeutics Inc.
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- Advanced Cell Technology Inc.
- Cellular Engineering Technologies Inc.
- CellGenix GmbH
- PromoCell GmbH
- Kite Pharma
- Genea Biocells
Recent Developments
-
A new drug application (IND) has been approved by FDA for Stemedica Cell Technologies, Inc. in order to treat moderate-to-severe COVID-19 with intravenous administration of allogeneic mesenchymal stem cells (MSCs). This new application has shown to be effective in treating the symptoms of moderate-to-severe COVID-19, such as inflammation, fever, and difficulty breathing.
-
An official announcement from Pluristem Therapeutics Inc. announced that the company's subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the Abu Dhabi Stem Cells Center (ADSCC), a special healthcare center for cell therapy and regenerative medicine based in the United Arab Emirates.
Author Credits:
- Report ID: 1329
- Published Date: Jun 13, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Stem Cell Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
